This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
19 Sep 2011

FDA Grants Orphan Drug Designation to Avedro's VibeX

The FDA has granted orphan drug designation to Avedro's VibeX solution for use with its KXL System for corneal cross-linking to treat keratoconus.

The US FDA has granted orphan drug designation to Avedro's VibeX (0.1.% riboflavin ophthalmic solution) for use with its KXL System (UVA irradiation) for corneal cross-linking to treat keratoconus.

 

The orphan drug designation, along with the encouraging clinical results from the Phase III keratoconus study, is an important step in bringing the technology to patients in the US, according to Avedro CEO David Muller.

 

Avedro has submitted an additional application for orphan drug designation for cross-linking for the treatment of corneal ectasia following refractive surgery.

Related News